ParaZero Technologies (PRZO) 20-F 21 Mar 24 2023 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2023 shares
Document Information Line Items
Entity Registrant Name	ParaZero Technologies Ltd.
Trading Symbol	PRZO
Document Type	20-F
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	10,073,956
Amendment Flag	false
Entity Central Index Key	0001916241
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	001-41760
Entity Incorporation, State or Country Code	L3
Entity Address, Address Line One	30 Dov Hoz
Entity Address, City or Town	Kiryat Ono
Entity Address, Postal Zip Code	5555626
Entity Address, Country	IL
Title of 12(b) Security	Ordinary Shares, par value NIS 0.02 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Financial Statement Error Correction [Flag]	false
Document Accounting Standard	U.S. GAAP
Auditor Firm ID	1197
Auditor Name	Brightman Almagor Zohar & Co
Auditor Location	Tel Aviv, Israel
Business Contract
Document Information Line Items
Entity Address, Address Line One	30 Dov Hoz
Entity Address, City or Town	Kiryat Ono
Entity Address, Postal Zip Code	55555626
Entity Address, Country	IL
Contact Personnel Name	Boaz Shetzer
City Area Code	+972
Local Phone Number	3-688-5252
Contact Personnel Email Address	contact@ParaZero.com

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 7,428,405	$ 89,806
Trade receivables	22,376	184,064
Other current assets	651,560	179,541
Deferred initial public offering costs		291,133
Inventories	264,468	304,823
TOTAL CURRENT ASSETS	8,366,809	1,049,367
NON-CURRENT ASSETS:
Operating lease right-of-use asset	8,127	56,893
Property and equipment, net	49,981	41,311
TOTAL NON-CURRENT ASSETS	58,108	98,204
TOTAL ASSETS	8,424,917	1,147,571
CURRENT LIABILITIES:
Trade payables	56,682	47,260
Operating lease liabilities	7,543	45,097
Other current liabilities	690,861	774,647
Convertible notes		1,514,928
TOTAL CURRENT LIABILITIES	755,086	2,381,932
NON-CURRENT LIABILITIES:
Derivative warrant liabilities	1,564,773
Operating lease liabilities, net of current portion		7,775
Loan from a related party		399,794
TOTAL NON-CURRENT LIABILITIES	1,564,773	407,569
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY (DEFICIT):
Ordinary shares, NIS 0.02 par value: Authorized 25,000,000 as of December 31, 2023 and December 31, 2022; Issued and outstanding 10,073,956 and 3,597,442 shares as of December 31, 2023 and as of December 31, 2022, respectively	56,227	21,456
Additional paid-in capital	24,471,888	12,988,292
Accumulated losses	(18,423,057)	(14,651,678)
TOTAL SHAREHOLDERS’ EQUITY (DEFICIT)	6,105,058	(1,641,930)
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)	$ 8,424,917	$ 1,147,571

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - ₪ / shares	Dec. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Ordinary shares, par value (in New Shekels per share)	₪ 0.02	₪ 0.02
Ordinary shares, share authorized	25,000,000	25,000,000
Ordinary shares, shares issued	10,073,956	3,597,442
Ordinary shares, shares outstanding	10,073,956	3,597,442

Statements of Comprehensive Los

Statements of Comprehensive Loss - USD ($)		12 Months Ended
		Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Sales		$ 620,508	$ 560,118	$ 724,391
Cost of Sales		476,610	337,565	464,715
Gross profit		143,898	222,553	259,676
Research and development expenses		636,801	640,328	603,702
Selling and marketing expenses		487,904	264,728	168,700
General and administrative expenses		1,472,872	766,711	474,703
Initial public offering expenses		345,925	389,396
Operating loss		2,799,604	1,838,610	987,429
Change in fair value of convertible notes		504,976
Change in fair value of derivative warrant liabilities		277,600
Issuance expenses attributable to derivate warrant liability		247,129
Interest expenses on related party loan		152,745	17,386
Other finance income, net		(210,675)	(202,958)	(372,048)
Net loss and comprehensive loss		$ 3,771,379	$ 1,653,038	$ 615,381
Net loss per ordinary share, basic (in Dollars per share)		$ 0.77	$ 0.49	$ 1.71
Weighted-average number of ordinary shares outstanding, basic (in Shares)	[1]	4,891,071	3,349,071	359,743
[1]See Note 2X.

Statements of Comprehensive L_2

Statements of Comprehensive Loss (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net loss per ordinary share, diluted	$ 0.77	$ 0.49	$ 1.71
Weighted-average number of ordinary shares outstanding, diluted	4,891,071	3,349,071	359,743

Statements of Changes In Shareh

Statements of Changes In Shareholders’ Equity (Deficit) - USD ($)	Ordinary shares	Additional paid-in Capital	Accumulated Losses	Total
Balance at Dec. 31, 2020	$ 1,945	$ 6,380,403	$ (12,383,259)	$ (6,000,911)
Balance (in Shares) at Dec. 31, 2020	359,743
Comprehensive loss			(615,381)	(615,381)
Balance at Dec. 31, 2021	$ 1,945	6,380,403	(12,998,640)	(6,616,292)
Balance (in Shares) at Dec. 31, 2021	359,743
Conversion of Former Parent Company’s debt into ordinary shares and warrants	$ 19,511	6,403,797		6,423,308
Conversion of Former Parent Company’s debt into ordinary shares and warrants (in Shares)	3,237,699
Stock based compensation		91,377		91,377
Benefit to the Company by an equity holder with respect to funding transactions		112,715		112,715
Comprehensive loss			(1,653,038)	(1,653,038)
Balance at Dec. 31, 2022	$ 21,456	12,988,292	(14,651,678)	$ (1,641,930)
Balance (in Shares) at Dec. 31, 2022	3,597,442			3,597,442
Stock based compensation		490,015		$ 490,015
Conversion of convertible note into ordinary shares	$ 2,734	2,017,170		2,019,904
Conversion of convertible note into ordinary shares (in Shares)	504,976
Issuance of ordinary shares and warrants upon initial public offering, net of issuance costs	$ 10,561	5,919,064		5,929,625
Issuance of ordinary shares and warrants upon initial public offering, net of issuance costs (in Shares)	1,950,000
Issuance of ordinary shares, pre-funded warrants, and warrants upon private placement, net of issuance costs (*)	$ 21,476	3,045,180		3,066,656
Issuance of ordinary shares, pre-funded warrants, and warrants upon private placement, net of issuance costs (*) (in Shares)	4,021,538
Benefit to the Company by an equity holder with respect to funding transactions		12,167		12,167
Comprehensive loss			(3,771,379)	(3,771,379)
Balance at Dec. 31, 2023	$ 56,227	$ 24,471,888	$ (18,423,057)	$ 6,105,058
Balance (in Shares) at Dec. 31, 2023	10,073,956			10,073,956

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,771,379)	$ (1,653,038)	$ (615,381)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	17,087	18,495	17,627
Stock based compensation	14,815	52,286
Interest expenses with respect to funding from related party	112,373	12,509
Change in fair value of convertible loan	504,976
Changes in fair value of derivative liabilities	277,600
Issuance expenses attributable to derivative warrant liabilities	247,129
Inventory write-down	33,360	12,387
Foreign currency exchange differences with respect to amount due to a Former Parent Company		(243,948)	(402,365)
Finance expenses	583	4,021	342
Changes in operating assets and liabilities:
Trade receivables, net	161,689	(176,863)	28,595
Other current assets	(472,020)	(96,782)	21,667
Deferred initial public offering cost		(252,041)
Inventories	6,995	34,205	6,738
Operating lease right-of-use asset	48,766	(48,633)	49,020
Trade payables	9,422	10,145	(35,764)
Operating lease liabilities	(45,911)	(48,975)	50,836
Other accounts payable	(83,785)	404,597	(107,213)
Net cash used in operating activities	(2,938,300)	(1,971,635)	(985,898)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(25,757)	(9,725)	(5,572)
Net cash used in investing activities	(25,757)	(9,725)	(5,572)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cost associated with the conversion of the Former Parent Company’s debt		(84,780)
Proceeds from issuance of convertible notes		1,514,928
Issuance of ordinary shares in initial public offering, net of issuance costs (Note 9c)	6,695,957
Issuance of ordinary shares, pre-funded warrants and warrants in private placement, net of issuance costs (Note 9b)	4,106,699
Receipt of loan from related party	245,000	500,000
Repayment of loan from related party	(745,000)
Receipt of loans from the Former Parent Company		107,994	940,624
Repayment of bank loan			(30,068)
Net cash provided by financing activities	10,302,656	2,038,142	910,556
Net (decrease) increase in cash and cash equivalents	7,338,599	56,782	(80,914)
Cash and cash equivalents at beginning of the year	89,806	33,024	113,938
Cash and cash equivalents at the end of the year	7,428,405	89,806	33,024
Supplementary disclosure on cash flows:
Cash paid for interest	40,000	4,876
Cash received from interest	53,804
Supplemental disclosure of non-cash investment and financing activities:
Right-of-use assets obtained in exchange for operating lease liabilities		97,532
Conversion of the Former Parent Company’s debt into ordinary shares		6,508,089
Benefit to the Company by an equity holder with respect to funding transactions	12,167	112,715
Conversion of convertible notes into ordinary shares	2,019,904
Stock based compensation included as issuance costs	$ 475,201	$ 39,091

General

General	12 Months Ended
	Dec. 31, 2023
General [Abstract]
GENERAL	NOTE 1 — GENERAL: A. PARAZERO TECHNOLOGIES LTD. - The Company sells its products internationally. The Company in October 2022, the Company entered into an unsecured credit facility agreement (the “Credit Facility Agreement”) with Medigus Ltd. (“Medigus”), a material shareholder of the Company, as further amended in June 2023, in an aggregate initial amount of up to $745 thousand, which was repaid in August 2023, following the completion of the IPO (see Note 9C3)). Furthermore, as noted above, on July 31, 2023, the Company raised $7.8 million from its IPO, and on October 30, 2023, the Company raised $5.1 million in a private investment in public equity (the “PIPE”) (see Note 9B). Management expects that it will require additional financing in the future to fund its operations until it has generated significant revenues. Based on the Company’s current operating plan, the Company’s management currently estimates that its cash position will support its current operations as currently conducted for more than 12 months from the date of issuance of these financial statements. B. On January 28, 2022, the Former Parent Company sold its shares in the Company to a consortium of investors led by Medigus and facilitated by L.I.A. Pure Capital Ltd., an Israeli venture capital firm. C. On . D. On each to purchase one Ordinary Share

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES: The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The significant accounting policies followed in the preparation of the financial statements are as follows: A. Use of estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as to disclose contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting years. On an ongoing basis, management evaluates its estimates, judgments and assumptions. Management bases its estimates, judgments and assumptions on historical experience and on various other factors that are believed to be reasonable under the circumstances. Actual results could differ from those estimates. B. Functional and foreign currency The financial statements of the Company are prepared in U.S. dollars (the functional currency), which is the currency of the primary economic environment in which the entity operates. The Company has funded its operations to date through financing mainly denominated in U.S. dollars and majority of the Company’s revenues during the years ended December 31, 2023, 2022 and 2021 were denominated in U.S. dollars. Transactions and balances that are denominated in currencies other than U.S. dollars have been remeasured into U.S. dollars in accordance with principles set forth in Accounting Standards Codification (“ASC”) 830, Foreign Currency Matters. Monetary assets and liabilities denominated in New Israeli Shekel (“NIS”) are remeasured into U.S. dollars at the end of each reporting period using the exchange rates in effect at the balance sheet date. Non-monetary assets and liabilities are measured at historical rates. Foreign currency transaction gains or losses are recorded in the statements of comprehensive loss as financing income or expenses, as appropriate. C. Cash and cash equivalents Cash and cash equivalents consist of cash and bank deposits with insignificant interest rate risk and original maturities of three months or less. D. Trade receivables Trade receivables are initially recognized at the invoiced amount less an allowance for estimated losses, if identified. E. Inventories The cost of inventories comprises all costs of purchase, and other costs incurred in bringing the inventories to their present location and condition. Inventories are stated at the lower of cost, determined by the first-in, first-out method, or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions. F. Property and equipment, net Property and equipment, net is stated at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis, over the useful lives of the assets at annual rates as follows: Years Computers 3-7 Research and Development equipment 6-7 Furniture and office equipment 17 Leasehold improvements Shorter of economic life or remaining lease term Depreciation expense was $17,087, $18,495, and $17,627 for the years ended December 31, 2023, 2022, and 2021, respectively. G. Fair value measurement The Company measures and discloses fair value in accordance with the Financial Accounting Standards Board (“FASB”), ASC 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 — unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. Level 2 — pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Level 3 — pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Level 3 inputs are considered as the lowest priority within the fair value hierarchy. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The carrying amounts of cash and cash equivalents, trade receivables, other current assets, trade payables and other account payables approximate their fair value due to the short-term maturity of such instruments. The Company’s financial liabilities measured at fair value on a recurring basis consisted of derivative warrant liabilities as of December 31, 2023 (level 3) and convertible notes as of December 31, 2022 (level 2). H. Initial public offering costs The Company capitalized certain legal, professional accounting and other third-party fees that were direct and incremental fees associated with new securities to be issued in the IPO, as deferred initial public offering costs in the balance sheet. Following the completion of the IPO, deferred initial public offering costs were recorded in stockholders’ equity as a reduction from gross proceeds within additional paid-in capital. Fees attributable to the resale of existing securities that were offered together with newly issued shares in the IPO were recognized as initial public offering expenses within the statement of comprehensive loss. As of December 31, 2023 and December 31, 2022, the Company recognized initial public offering expenses of $345,925 and $389,396 respectively, within the statement of comprehensive loss. I. Loans from Related Party During fiscal years 2023 and 2022, the Company signed a Credit Facility Agreement with a related party. On the borrowing date of loans with related parties, the Company estimates the value of the benefit granted to it as the difference between the interest rate that the Company is required to pay to investors for the loans provided by them and the interest rate required to pay for similar unsecured loans to non-related parties. The value of the benefit was recorded within shareholders’ equity on the borrowing date. J. Convertible notes In accordance with ASC 480-10, “Accounting for Certain Financial instruments with Characteristics of both Liabilities and Equity inancial instruments that have characteristics of both liabilities and equity are classified as liabilities and are initially and subsequent to issuance measured at fair value, if at inception such instruments, in the predominant scenario, may be settled either by issuing a variable number of shares that in the aggregate provide a fixed monetary value, by issuing a variable number of shares that is inversely related to changes in the fair value of the Company’s share or by issuing a variable number of shares that is based on variations in an observable market or index, other than a market of index measured by reference to the fair value of the Company’s share. The Company issued convertible notes (see Note 7) to investors and related parties in 2022. Such convertible notes embodied a conditional obligation for the Company to issue a variable number of shares based on a fixed monetary amount known at inception and as such were classified as liabilities and were initially and subsequent to issuance measured at fair value. K. Warrants classification When the Company issues freestanding instruments, it first analyzes the provisions of the Financial Accounting Standards Board (“FASB”) ASC Topic 480, Distinguishing Liabilities from Equity Derivatives and Hedging L. Warranty reserve The Company provides a one-year standard warranty for its products. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. As of December 31, 2023 and December 31, 2022, the Company recorded under the other current liabilities line item a provision of $5,793 and $9,136 respectively. M. Stock based compensation The Company accounts for stock based compensation under ASC Topic 718, Compensation - Stock Compensation stock based stock options The Company recognizes compensation expenses for the value of its awards granted based on the graded -vesting method over the requisite service period for each separately vesting portion of the award. Forfeitures are accounted for as they occur. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s statements of comprehensive loss. The Black-Scholes option-pricing model requires the Company to make several assumptions, of which the most significant are the fair market value of the underlying ordinary shares, expected share price volatility and the expected option term. Expected volatility was calculated based on the implied volatilities from market comparisons of certain publicly traded companies that operate in the same industry as the Company. The expected option term represents the period of time that options granted are expected to be outstanding. The expected option term is determined based on the simplified method in accordance with Staff Accounting Bulletin No. 110, as adequate historical experience is not available to provide a reasonable estimate. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. The assumptions used to determine the fair value of the stock based awards are management’s best estimates and involve inherent uncertainties and the application of judgment. N. Recently issued accounting pronouncements As an emerging growth company, the Jumpstart Our Business Startup Act of 2012 (the “JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The Company adopted the following accounting standards during the year: On January 1, 2023, the Company adopted ASU No. 2016-13, “ Financial Instruments – Credit Losses The following are accounting pronouncements that are not yet effective for the Company: In August 2020, FASB issued ASU 2020-06, “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging- Contracts in Entity’s Own Equity (Subtopic 815-40).” The amendments in this update affect entities that issue convertible instruments and/or contracts in an entity’s own equity. For convertible instruments, the instruments primarily affected are those issued with beneficial conversion features or cash conversion features because the accounting models for those specific features are removed. This ASU is effective for the Company starting on January 1, 2024. The Company does not believe that the adoption of this standard will have a material impact on the Company’s financial statements. In November 2023, the FASB issued ASU 2023-07, “ Segment Reporting (Topic 280) In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) – “ Improvements to Income Tax Disclosures O. Revenue recognition Revenue is recognized when (or as) control of the promised goods or services is transferred to the customer, and in an amount that reflects the consideration the Company is contractually due in exchange for those services or goods. The Company follows five steps to record revenue: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies its performance obligations. The Company’s revenues consist of sales of drone safety systems (“products”) with a one-year warranty, directly to system manufactures, resellers and an online store. The payments terms are usually an advance payment through a credit card, bank wire or 30 days credit upon delivery of the product for certain existing clients. The Company recognizes revenue from the sale of products at the point of time when control is transferred to its customers. Once the products have been physically delivered to the agreed location, the Company no longer has physical pos but has a present right to receive payment without retaining any significant risks or benefits. The products include warranties that require the Company to either replace or repair defective products during the warranty period if the products fail to comply with their described specifications. Such warranties are not accounted for as separate performance obligations and hence no revenue is allocated to them. Instead, a provision is made for the costs of satisfying the warranties. Q. Cost of sales Cost of sales consists primarily of expenses related to the purchase of materials of products sold, royalties, warranty costs, salary and related expenses. R. Research and development cost Research and development expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as incurred. S. Leases The Company accounts for leases in accordance with ASC 842 “ Leases . The Company has elected the practical expedient to include lease and non-lease components as a single lease component. Additionally, the Company has made a policy election not to recognize operating lease right-of- use assets and lease liabilities on leases with original terms of 12 months or less. Payments for variable lease costs are expensed as incurred and are not included in the operating lease ROU assets and lease liabilities. In accordance with ASC 360-10, management reviews operating lease assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable based on estimated future undiscounted cash flows. If so indicated, an impairment loss would be recognized for the difference between the carrying amount of the asset and its fair value. U. Income taxes The Company accounts for income taxes in accordance with ASC 740 (Income Taxes) (“ASC 740”). Deferred taxes are determined utilizing the assets and liabilities method, which is based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all the deferred tax assets will not be realized. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefits that, based on available evidence, are not expected to be realized. As of December 31, 2023 and 2022, the Company recorded a full valuation allowance against its deferred tax assets. The Company applies ASC 740, which clarifies the accounting and reporting for uncertainties with respect to income taxes. ASC 740 prescribes a comprehensive model for the financial statement recognition, measurement, presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. As of December 31, 2023 and 2022, no liability for uncertain tax positions were recorded. V. Severance pay Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. All of the Company’s employees are covered under Section 14 of the Severance Pay Law, 1963 (“Section 14”) Pursuant to Section 14, the Company’s employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with Section 14 relieve the Company from any future severance payments in respect of those employees. W. Commitments and contingencies Liabilities for loss contingencies arising from claims, assessments, litigations, fines and penalties and other sources are recognized in accordance with ASC No. 450, “ Contingencies X. Basic and diluted loss per share Loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares outstanding during Y. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents.

Other Current Assets

Other Current Assets	12 Months Ended
	Dec. 31, 2023
Other Current Assets [Abstract]
OTHER CURRENT ASSETS	NOTE 3 — OTHER CURRENT ASSETS: December 31 2023 2022 Governmental institutions 233,501 120,126 Prepaid expenses 349,632 59,415 Other current assets 68,427 - Total 651,560 179,541

Inventories

Inventories	12 Months Ended
	Dec. 31, 2023
Inventories [Abstract]
INVENTORIES	NOTE 4 — INVENTORIES: December 31 2023 2022 Raw materials 261,192 284,028 Finished goods 3,276 20,791 Total 264,468 304,823 For the years ended December 31, 2023, 2022 and 2021, the Company wrote off inventory in the amount approximately $33 thousand, $12 thousand and $0

Leases

Leases	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Leases	NOTE 5 — The Company had a two-year lease agreement for its office in Kiryat Ono, Israel that began in 2020, and was renewed in 2022 for an additional two years that ended in February 2024. The annual lease payment was approximately $50 thousand. In February 2024, the Company entered into a new lease agreement on different premises (see Note 16C) and extended the previous lease agreement by one month that ends in March 2024. As of December 31, 2023, the new operating lease had not commenced and was excluded from the tables below. The Company’s lease expenses were as follows: Year ended 2023 2022 2021 Lease expense $ 45,891 $ 47,425 $ 50,103 Other information related to operating leases as follows: December 31, 2023 2022 2021 Weighted-average remaining lease term — operating leases (years) 0.166 1.166 1.166 Weighted-average discount rate — operating leases (%) 6.00 6.00 6.00 Undiscounted maturities of operating lease payments are summarized as follows: December 31, 2024 $ 8,126 Total undiscounted cash flows $ 8,126 Less: imputed interest $ 583 Operating lease liabilities $ 7,543

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2023
Property and Equipment, Net [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 6 — PROPERTY AND EQUIPMENT, NET: Leasehold improvements Computers Furniture and office equipment R&D equipment Total Cost: Balance as of January 1, 2022 94,805 5,572 30,596 — 130,973 Additions during the year — 9,725 — — 9,725 Balance as of December 31, 2022 94,805 15,297 30,596 — 140,698 Additions during the year — 9,037 677 16,043 25,757 Balance as of December 31, 2023 94,805 24,334 31,273 16,043 166,455 Accumulated depreciation: Balance as of January 1, 2022 69,213 3,586 8,093 — 80,892 Additions during the year 14,216 1,774 2,505 — 18,495 Balance as of December 31, 2022 83,429 5,360 10,598 — 99,387 Additions during the year 9,490 4,026 2,548 1,023 17,087 Balance as of December 31, 2023 92,919 9,386 13,146 1,023 116,474 Net book value: As of December 31, 2023 1,886 14,948 18,127 15,020 49,981 As of December 31, 2022 11,376 9,937 19,998 — 41,311

Convertible Notes

Convertible Notes	12 Months Ended
	Dec. 31, 2023
Convertible Notes [Abstract]
CONVERTIBLE NOTES	NOTE 7 — CONVERTIBLE NOTES: In February, March and May 2022, the Company entered into certain SAFEs, as further amended in July 2023, with certain investors including related parties, officers and directors. As of December 31, 2022, the Company had received approximately $1,514,928 (such amount for each investor, the “Investment Amount”). The SAFEs provided for the conversion of the Investment Amount into the Company’s Ordinary Shares under certain circumstances: 1. Upon the occurrence of an initial public offering-event immediately prior to the closing of such initial public offering of the Company, the Investment Amount automatically converted into such number of Ordinary Shares and warrants, as applicable, issued in the initial public offering equal to the initial public offering price discounted by 25%. 2. Optional conversion following a written notice made at investor’s sole discretion equal to the purchase amount discounted by 20%. 3. In the event of liquidity event and dissolution event. 4. Mandatory conversion upon drop date — If the Investment Amount had not been converted prior to October 31, 2023 (the “Drop Date”), then on such Drop Date, the SAFE would have been automatically converted into such number of the most senior class of equity shares of the Company then outstanding, equal to, the Investment Amount, divided by the lowest price per share actually paid to the Company for such most senior class of equity shares of the Company then outstanding in an investment transaction by a third party on or after January 1, 2022, discounted by 20%. If such investment transaction did not occur by January 1, 2022, then the SAFE would have automatically converted into such number of the most senior class of equity shares of the Company then outstanding, equal to, the Investment Amount, divided by AUD3.313 (approximately $2.30) (subject to any customary adjustments for share splits and consolidations). As the conversion rate was not indexed to the Company’s share price, the Company accounted for the SAFEs as a liability which subsequently measured at fair value. On July 31, 2023, following the closing of the IPO, the aggregate amount of $1,514,928 received under the SAFE, was converted at a price equal to the IPO price discounted by 25%, into 504,976 Ordinary Shares of the Company. The Company recorded a finance expense of $504,976 for the year ended December 31, 2023 with respect to the change in the fair value of the SAFEs upon conversion.

Other Accounts Payable

Other Accounts Payable	12 Months Ended
	Dec. 31, 2023
Other Accounts Payable [Abstract]
OTHER ACCOUNTS PAYABLE	NOTE 8 — OTHER ACCOUNTS PAYABLE: December 31 2023 2022 Employees, salaries and related liabilities 195,509 137,597 Advances from customers 201,762 185,002 Warranty provision 5,793 9,136 Accrued expenses 287,797 442,912 690,861 774,647

Shareholders' Equity (Deficit)

Shareholders' Equity (Deficit)	12 Months Ended
	Dec. 31, 2023
Shareholders Equity Deficit [Abstract]
SHAREHOLDERS' EQUITY (DEFICIT)	NOTE 9 — SHAREHOLDERS’ EQUITY (DEFICIT): A. SHARE CAPITAL The Ordinary Shares entitle their holders: to receive notices of, and to attend, general meetings where each Ordinary Share shall have one vote for all purposes; to share distributions as may be declared by the Board of Directors of the Company and approved by the shareholders, if required; and, upon liquidation or dissolution — to participate in the distribution of the assets of the Company after payment of all debts and other liabilities of the Company, in accordance with the terms of the Company’s Articles of Association (the “Articles of Association”). In January 2024 the Company increased the number of authorized ordinary shares (See Note 16A). B. PRIVATE PLACEMENT On October 26, 2023, the Company entered into the PIPE with certain accredited investors for aggregate gross proceeds of approximately $5.1 million, before deducting fees to the placement agent and other expenses payable by the Company (the “issuance expenses”) of $975,811. The PIPE closed on October 30, 2023. As part of the PIPE, the Company issued an aggregate of (i) 1,136,364 Ordinary Shares, (ii) 3,500,000 pre-funded warrants each to purchase one Ordinary Share at an exercise price of $0.005 and, (iii) series B warrants convertible into an aggregate of up to 140,373 Ordinary Shares at an exercise price $0.005 (following the end of an adjustment period as further described below). The pre-funded warrants are exercisable as of December 31, 2023 and will not expire until exercised in full. Additionally, the Company issued 4,636,364 series A warrants each to purchase one Ordinary Share at an exercise price of $1.10 per Ordinary Share (subject to customary adjustments and certain anti-dilution adjustments), and were immediately exercisable for a period of 5.5 years from the date of issuance. The number of Ordinary Shares issuable under the series B warrant was initially subject to an adjustment determined by the trading price of the Ordinary Shares following the effectiveness of a resale registration statement (the “Resale Registration Statement”) (see below) that the Company undertook to file, subject to a pricing floor of $0.50 per Ordinary Share, such that the maximum number of Ordinary Shares underlying the series B warrants would have been be an aggregate of 5,563,638 shares. Following the effectiveness of the Resale Registration Statement, on December 14, 2023, the number of Ordinary Shares underlying the series B warrants was adjusted to an aggregate of 140,373 Shares. Subsequent to such adjustment, the series B warrants have substantially the same terms as the pre-funded warrants. During December 2023, certain warrant holders exercised 2,894,548 pre-funded warrants and 8,257 series B warrants via a cashless exercise mechanism for which they received 2,876,957 and 8,217 Ordinary Shares respectively. As of December 31, 2023, the remaining outstanding pre-funded, series A and series B warrants were 605,452, 4,636,364 and 132,116, respectively. The series A warrants have certain features that preclude equity classification; therefore, the series A warrants were accounted for as derivate warrant liabilities recorded at fair value (See note 11A). The PIPE proceeds were first allocated to the derivative warrant liabilities based on its fair value of $1,287,173 at the date of issuance with the remaining proceeds allocated to the equity instruments in the amount of $3,795,338, prior to the allocation of issuance expenses ($3,066,656 net of issuance expenses). The Company expensed a portion of the issuance expenses attributable to the derivative warrant liabilities. Such portion which amounted to $247,129 was determined based on the proportion of the fair value of the derivative warrant liabilities on the issuance date to gross proceeds from the PIPE and recorded in the statement of comprehensive loss for the year ended December 31, 2023. C. IPO On July 31, 2023, the Company issued and sold in connection with the closing of the IPO 1,950,000 Ordinary Shares at a price to the public of $4.00 per share. In addition, the Company granted the underwriters a 45-day option to purchase up to 292,500 additional ordinary shares at the initial price to the public, less underwriting discounts and commissions, to cover over-allotments. The 45-day option was not exercised by the underwriters. In connection with the IPO, the Company received gross proceeds of approximately $7.8 million before deducting underwriting discounts and commissions and before offering expenses ($5.8 million net proceeds after deducting approximately $0.8 million of underwriting discounts and commissions and approximately $1.2 million of other offering costs). The Ordinary Shares were approved for listing on the Nasdaq Capital Market and commenced trading under the symbol “PRZO” on July 27, 2023. In connection with the closing of the IPO, the following transactions took place: 1) All of the SAFEs representing an aggregate amount of $1,514,928 were converted into 504,976 Ordinary Shares of the Company. The fair value of the SAFEs prior to the conversion was $2,019,904. See Note 7 above. 2) The Company issued warrants to the underwriters to purchase up to an aggregate of 97,500 Ordinary Shares at an exercise price of $5.00 per share, exercisable during the five-year period commencing on the date that is six months from July 31, 2023. The fair value of the warrants issued to the underwriters of $93,600 was accounted for as an issuance cost charged to equity. 3) The Company repaid the used credit facility received from a related party in an aggregate amount of $745 thousand 4) During 2022, the Company entered into a consulting agreement with two consultants by which the Company would issue 179,510 warrants to each consultant upon the consummation of a qualified equity transaction. Each whole warrant would be exercisable to purchase one Ordinary Share of the Company, at an exercise price equal to the par value of the Company’s Ordinary Shares (NIS 0.02 or approximately $0.00555 per Ordinary Share), which may be paid also via cashless exercise at any time after the six-month anniversary of the grant date exercisable until August 9, 2028. The warrants were issued upon the consummation of the IPO and were fully vested on the issuance date and are exercisable at any time and from time to time, in whole or in part for a period of five years from the date of their grant. Considering the de-minimis exercise price, the fair values of the warrants were determined, taking into consideration the ordinary share price on the grant date and likelihood of attaining the performance condition. The total grant date fair value of the warrants was $387,660 thousand which was fully expensed upon the completion of the IPO. Total stock-based compensation expenses for the period ended December 31, 2022 was $91,377 of which $39,091 was capitalized within deferred initial public offering cost. For the year ended December 31, 2023, the Company incurred $296,283 of stock-based compensation expenses that was recorded as an issuance cost within shareholders’ equity net of the IPO proceeds. 5) The Company issued to its advisor 144,606 warrants, with each whole warrant exercisable for one Ordinary Share . Each whole warrant is exercisable to purchase one Ordinary Share of the Company, which may be paid also via cashless exercise at any time after the six-month anniversary of the grant date, D E F G H.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2023
Share-Based Compensation [Abstract]
STOCK-BASED COMPENSATION	NOTE 10 — STOCK-BASED COMPENSATION: The Company’s Global Share Incentive Plan (2022) (the “Plan”) was adopted by Company’s Board of Directors on March 28, 2022. The Plan provides for the grant of options to purchase Ordinary Shares, restricted share units representing Ordinary Shares and Ordinary Shares (collectively, the “Awards”) to the Company’s employees, officers, directors, advisors and consultants in order to promote a close identity of interests between those individuals and us. The total number of Ordinary Shares reserved for issuance under the Plan is 610,156 Ordinary Shares. As of the date of this report, 243,984 Ordinary Shares remain available for future awards under the Plan. Ordinary Shares subject to Awards granted under the Plan that expire, are forfeited or otherwise terminated without having been exercised in full will become available again for future grant under the Plan. On September 20, 2023, the Company’s Board of Directors approved the grant of an aggregate of 366,172 options to purchase Ordinary Shares to certain employees and directors. Options granted to certain officers and directors require shareholder approval which was obtained in a shareholder general meeting on November 2, 2023. The exercise price of such options is $1.275 per Ordinary Share, exercisable for a period of 5 years from the grant date. Such options vest over four A summary of the stock option activity for the year ended December 31, 2023 is as follows: Number of Weighted Options outstanding as of December 31, 2022 - Granted 366,172 $ 1.275 Options outstanding as of December 31, 2023 366,172 $ 1.275 Options exercisable as of December 31, 2023 - $ - As of December 31, 2023, the weighted-average remaining contractual life of the outstanding options were 4.7 years. The Company used the Black-Scholes option-pricing model to determine the fair value of options granted during 2023. The following assumptions were applied in determining the options’ fair value on their grant date: 2023 Risk-free interest rate 4.51%-4.67% Expected option term (years) 3.8-5 Expected share price volatility 61.1%-66.3 % Dividend yield - As of December 31, 2023, the Company had 366,172 unvested options. As of December 31, 2023, the unrecognized compensation cost related to all unvested options of $197,384 is expected to be recognized as an expense on a straight-line basis over a weighted-average period of 3.8 years. The intrinsic value of the options expected to vest as of December 31, 2023 was $0.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2023
Warrants [Abstract]
WARRANTS	NOTE 11 —WARRANTS: A. Derivatives warrant liabilities As part of the PIPE the Company issued to accredited investors Units each consisting of (i) one Ordinary Share or pre-funded warrant, (ii) one series A warrant and (iii) one series B warrant, see Note 9B above. The terms of the series A warrants issued include certain features that preclude equity classification; therefore, they were classified as liabilities with changes in fair value recognized in profit or loss. Additionally, the terms include a cashless exercise provision and repricing provisions, under certain circumstances. The fair value of the series A warrants issued in the PIPE at the time of the initial closing, which took place on October 30, 2023, and on December 31, 2023, was calculated by an independent valuation expert, performing numerous iterations using the Black–Scholes option price model, based on a probability of a down round protection adjustment event and using the following assumptions: October 30, December 31, Expected volatility (%) 55.95%-59.37% 55.08%-60.24 Risk-free interest rate (%) 4.78%-4.99% 3.85%-4.05% Expected Life (years) 2-5 2-5 Value per share $0.59 $0.71 Exercise price (U.S. dollars per share) $1.1 $1.1 The following table sets forth the fair value changes of the series A warrants during the year ended December 31, 2023: Balance as of December 31, 2022 - Initial measurement 1,287,173 Change in fair value 277,600 Balance as of December 31, 2023 1,564,773 B. Equity warrant Warrants issued as part of the Delta Drone transaction with the Former Parent Company and upon the IPO completion: Issuance date In connection with No. of Exercise No. of 2022* Delta Drone Warrants 111,261 $ 4.00 111,261 2023** IPO Underwriter Warrants 97,500 $ 5.00 97,500 2023*** IPO Consultants Warrants 359,020 $ 0.00555 359,020 2023**** IPO Consultants Warrants 144,606 $ 1.275 144,606 * see Note 12B ** see Note 9C2) *** see Note 9C4) **** see Note 9C5)

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12 — COMMITMENTS AND CONTINGENCIES: A. Israel Innovation Authority: The Company has received royalty-bearing grants from the Israel Innovation Authority (the “IIA”), for approved research and development projects. The programs include grants for: wages, materials, subcontractors and miscellaneous. The Company is required to pay royalties at the rate of 3%-3.5% depending on meeting certain conditions on sales of the products developed with the funds provided by the IIA, up to an amount equal to 300% of the IIA research and development grant received, depending upon the manufacturing volume that is performed outside of Israel, indexed to the U.S. dollar and bearing interest., Until December 31, 2023, the interest was calculated at a rate based on an annual application of the London Interbank Offered Rate, or the LIBOR, applicable to U.S. dollar deposits, however, pursuant to the latest IIA regulations, as of January 1, 2024, IIA grants received after June 30, 2017, shall bear interest calculated at a rate based on an annual application of the SOFR, or at an alternative rate published by the Bank of Israel, plus approximately 0.72%. indexed to the dollar including accrued interest at the SOFR rate. As of December 31, 2019, the research and development projects funded by the IIA were completed. The total amount of the IIA grant received was $748 thousand. As of December 31, 2023, the maximum obligation with respect to the grants received from the IIA, including accrued interest, contingent upon entitled future sales, is $613 thousand. revenues recorded between the years 2019-2023, of the products developed with the funds provided by the IIA. When a company develops know-how, technology or products using IIA grants, the terms of these grants and the Research Law restrict the transfer of such know-how, and the transfer of manufacturing or manufacturing rights of such products, technologies or know-how outside of Israel, without the prior approval of the IIA. Therefore, the discretionary approval of an IIA committee would be required for any transfer to third parties inside or outside of Israel of know-how or manufacturing or manufacturing rights related to those aspects of such technologies. There is no certainty that the Company would obtain such approvals B. Former Parent Company On January 28, 2022, the Former Parent Company announced it had entered into a binding agreement with a consortium of investors led by Medigus and facilitated by Israeli venture capital firm L.I.A. Pure Capital Ltd (“Pure Capital”), for the sale of 100% of the share capital of the Company for a total consideration of Australian Dollar (“AUD”) 6 million (approximately $4.2 million) in cash (the “Acquisition”), and all outstanding liabilities between the Company and the Former Parent Company were converted into equity immediately prior to the closing of the Acquisition. On February 2, 2022 (the “Issue Date”), the Company issued to the Former Parent Company a warrant to purchase 111,261 Ordinary Shares. The exercise price of such warrant is (A) if a Trigger Event (defined below) occurs, the price per Company Ordinary Shares in the IPO, or, (B) if a Trigger Event has not occurred, US $2.7797 per each Company Ordinary Shares, reflecting a pre-money valuation of US $10,000,000 on a fully diluted as-converted basis as of the Issue Date. Further, (A) if an IPO of the Company occurs before the fifth anniversary of the Issue Date, then the warrant shall expire after the lapse of 90 days from the earlier of (“Trigger Event”): (i) the fifth anniversary of the Issue Date; or (ii) the price per each Company Ordinary Shares has increased by at least 50% compared to the listing price per Company Ordinary Shares as part of the IPO (to be determined based upon one-calendar-month volume weighted average price); and (B) if no IPO of the Company occurs before the lapse of the fifth anniversary of the Issue Date, then the warrant shall expire after the lapse of 12 months from the fifth anniversary of the Issue Date. As of December 31, 2023, following the closing of the IPO, the number of the outstanding warrants is 111,261 with an exercise price of $4.00 per ordinary share and expiration date of no later than July 31, 2028.

Loan from Related Party

Loan from Related Party	12 Months Ended
	Dec. 31, 2023
Loan from Related Party [Abstract]
LOAN FROM RELATED PARTY	NOTE 13 — LOAN FROM RELATED PARTY: In August 2022, the Company received a $250 thousand loan from Medigus bearing an interest rate of 8% per annum, to be repaid upon the earlier of (i) August 4, 2024, (ii) the date the Company closes an equity financing round, which would include IPO, (iii) the date on which the Company will receive a bank financing or (iv) the occurrence of certain events of default. On October 30, 2022, the Company terminated the Medigus Loan and repaid the balance of $250 thousand plus the accrued interest ($4,876), in accordance with the loan agreement. On October 30, 2022, the Company entered into the Credit Facility Agreement with Medigus to borrow from time to time amounts from Medigus for the purposes of financing the ongoing activities and the payment of certain expenses in connection with the IPO Pursuant to the Credit Facility Agreement, as of October 30, 2022, Medigus made available to the Company credit facility with an aggregate initial amount of up to $625 thousand. On June 26, 2023, the Company amended the Credit Facility Agreement with Medigus to increase the amount of the Credit Facility to up to $745 thousand. As of December 31, 2022, and June 30, 2023, the Company received from Medigus $500 thousand and $745 thousand, respectively. The Credit Facility bears no interest, and the outstanding credit shall be due and payable on the earlier of (i) one year from the date of the Credit Facility Agreement (The Company may extend such time by up to six months), (ii) the closing of the Company’s IPO or (iii) the occurrence of certain events of default. If the outstanding credit is repaid in connection with the closing of the Company’s IPO, the Company will be obligated to make a one-time payment of an additional $40,000 to Medigus. On the borrowing date, the Company estimated the value of the benefit received based on the interest rate that the Company would be required to pay for similar unsecured loans to non-related parties. The value of the benefit was recorded within shareholders’ equity on each borrowing date. The accumulated interest expenses calculated as of December 31, 2023 and December 31, 2022 in the amount of $7,073 and $10,396 respectively, were charged to finance expenses. The used credit facility in an aggregate amount of $745 thousand was fully repaid in August 2023, following the closing of the IPO.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
INCOME TAXES	NOTE 14 — INCOME TAXES: A Corporate tax rate: The standard tax rate in Israel was 23% during the years ended December 31, 2023, 2022 and 2021. Tax assessments of the Company through tax year 2017 B. Deferred tax assets and liabilities: Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred taxes are computed using the standard tax rates of 23%. Significant components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2023 2022 Net operating loss carry forward $ 3,612,947 $ 2,693,459 Research and development expenses 145,249 135,367 Provision for warranty 1,332 2,101 Provision for vacation and convalescence 17,459 15,799 Issuance cost 81,010 86,464 Total deferred tax assets 3,857,998 2,933,190 Less - valuation allowance (3,857,998 ) (2,933,190 ) Net deferred tax assets $ - $ - In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences or carry-forwards are deductible. Based on the level of historical taxable losses, management has recorded a full valuation allowance on its deferred tax assets. C As of December 31, 2023 and December 31, 2022, the operating loss carry-forwards amounted to approximately $15.7 million and $12.7 million, respectively. Operating losses in Israel may be carried forward indefinitely to offset against future taxable operational income. D. Reconciliation of the theoretical tax expense to actual tax expense: The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision for a full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).

Transactions with Related Parti

Transactions with Related Parties	12 Months Ended
	Dec. 31, 2023
Transactions with Related Parties [Abstract]
TRANSACTIONS WITH RELATED PARTIES	NOTE 15 — TRANSACTIONS WITH RELATED PARTIES: A. B. C.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 16 — SUBSEQUENT EVENTS: A B. C. The monthly aggregate rental payment is NIS 71,000 plus VAT, as required under Israeli law. At the end of the term, the Company has an option to extend the lease for additional three years. In addition, the Company

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2023
Significant Accounting Policies [Abstract]
Use of estimates	A. Use of estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as to disclose contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting years. On an ongoing basis, management evaluates its estimates, judgments and assumptions. Management bases its estimates, judgments and assumptions on historical experience and on various other factors that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.
Functional and foreign currency	B. Functional and foreign currency The financial statements of the Company are prepared in U.S. dollars (the functional currency), which is the currency of the primary economic environment in which the entity operates. The Company has funded its operations to date through financing mainly denominated in U.S. dollars and majority of the Company’s revenues during the years ended December 31, 2023, 2022 and 2021 were denominated in U.S. dollars. Transactions and balances that are denominated in currencies other than U.S. dollars have been remeasured into U.S. dollars in accordance with principles set forth in Accounting Standards Codification (“ASC”) 830, Foreign Currency Matters. Monetary assets and liabilities denominated in New Israeli Shekel (“NIS”) are remeasured into U.S. dollars at the end of each reporting period using the exchange rates in effect at the balance sheet date. Non-monetary assets and liabilities are measured at historical rates. Foreign currency transaction gains or losses are recorded in the statements of comprehensive loss as financing income or expenses, as appropriate.
Cash and cash equivalents	C. Cash and cash equivalents Cash and cash equivalents consist of cash and bank deposits with insignificant interest rate risk and original maturities of three months or less.
Trade receivables	D. Trade receivables Trade receivables are initially recognized at the invoiced amount less an allowance for estimated losses, if identified.
Inventories	E. Inventories The cost of inventories comprises all costs of purchase, and other costs incurred in bringing the inventories to their present location and condition. Inventories are stated at the lower of cost, determined by the first-in, first-out method, or market based on net realizable value. Inventories are adjusted for estimated excess and obsolescence and written down to net realizable value based upon estimates of future demand, technology developments, and market conditions.
Property and equipment, net	F. Property and equipment, net Property and equipment, net is stated at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis, over the useful lives of the assets at annual rates as follows: Years Computers 3-7 Research and Development equipment 6-7 Furniture and office equipment 17 Leasehold improvements Shorter of economic life or remaining lease term Depreciation expense was $17,087, $18,495, and $17,627 for the years ended December 31, 2023, 2022, and 2021, respectively.
Fair value measurement	G. Fair value measurement The Company measures and discloses fair value in accordance with the Financial Accounting Standards Board (“FASB”), ASC 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820 defines fair value, establishes a framework and gives guidance regarding the methods used for measuring fair value, and expands disclosures about fair value measurements. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, there exists a three-tier fair-value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 — unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date. Level 2 — pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Level 3 — pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Level 3 inputs are considered as the lowest priority within the fair value hierarchy. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The carrying amounts of cash and cash equivalents, trade receivables, other current assets, trade payables and other account payables approximate their fair value due to the short-term maturity of such instruments. The Company’s financial liabilities measured at fair value on a recurring basis consisted of derivative warrant liabilities as of December 31, 2023 (level 3) and convertible notes as of December 31, 2022 (level 2).
Initial public offering costs	H. Initial public offering costs The Company capitalized certain legal, professional accounting and other third-party fees that were direct and incremental fees associated with new securities to be issued in the IPO, as deferred initial public offering costs in the balance sheet. Following the completion of the IPO, deferred initial public offering costs were recorded in stockholders’ equity as a reduction from gross proceeds within additional paid-in capital. Fees attributable to the resale of existing securities that were offered together with newly issued shares in the IPO were recognized as initial public offering expenses within the statement of comprehensive loss. As of December 31, 2023 and December 31, 2022, the Company recognized initial public offering expenses of $345,925 and $389,396 respectively, within the statement of comprehensive loss.
Loans from Related Party	I. Loans from Related Party During fiscal years 2023 and 2022, the Company signed a Credit Facility Agreement with a related party. On the borrowing date of loans with related parties, the Company estimates the value of the benefit granted to it as the difference between the interest rate that the Company is required to pay to investors for the loans provided by them and the interest rate required to pay for similar unsecured loans to non-related parties. The value of the benefit was recorded within shareholders’ equity on the borrowing date.
Convertible notes	J. Convertible notesIn accordance with ASC 480-10, “Accounting for Certain Financial instruments with Characteristics of both Liabilities and Equity”, financial instruments that have characteristics of both liabilities and equity are classified as liabilities and are initially and subsequent to issuance measured at fair value, if at inception such instruments, in the predominant scenario, may be settled either by issuing a variable number of shares that in the aggregate provide a fixed monetary value, by issuing a variable number of shares that is inversely related to changes in the fair value of the Company’s share or by issuing a variable number of shares that is based on variations in an observable market or index, other than a market of index measured by reference to the fair value of the Company’s share.The Company issued convertible notes (see Note 7) to investors and related parties in 2022. Such convertible notes embodied a conditional obligation for the Company to issue a variable number of shares based on a fixed monetary amount known at inception and as such were classified as liabilities and were initially and subsequent to issuance measured at fair value.
Warrants classification	K. Warrants classification When the Company issues freestanding instruments, it first analyzes the provisions of the Financial Accounting Standards Board (“FASB”) ASC Topic 480, Distinguishing Liabilities from Equity (“ASC 480”) in order to determine whether the instrument should be classified as a liability, with subsequent changes in fair value recognized in the statements of comprehensive loss in each period. If the instrument is not within the scope of ASC 480, the Company further analyzes the provisions of FASB ASC Topic 815, Derivatives and Hedging (“ASC 815-40”) in order to determine whether the instrument is considered indexed to the entity’s own stock, and qualifies for classification within equity. If the provisions of ASC 815-40 for equity classification are not met, the instrument is classified as a liability, with subsequent changes in fair value recognized in the statements of comprehensive loss in each period.
Warranty reserve	L. Warranty reserveThe Company provides a one-year standard warranty for its products. The Company records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary. As of December 31, 2023 and December 31, 2022, the Company recorded under the other current liabilities line item a provision of $5,793 and $9,136 respectively.
Stock based compensation	M. Stock based compensation The Company accounts for stock based compensation under ASC Topic 718, Compensation - Stock Compensation stock based stock options The Company recognizes compensation expenses for the value of its awards granted based on the graded -vesting method over the requisite service period for each separately vesting portion of the award. Forfeitures are accounted for as they occur. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s statements of comprehensive loss. The Black-Scholes option-pricing model requires the Company to make several assumptions, of which the most significant are the fair market value of the underlying ordinary shares, expected share price volatility and the expected option term. Expected volatility was calculated based on the implied volatilities from market comparisons of certain publicly traded companies that operate in the same industry as the Company. The expected option term represents the period of time that options granted are expected to be outstanding. The expected option term is determined based on the simplified method in accordance with Staff Accounting Bulletin No. 110, as adequate historical experience is not available to provide a reasonable estimate. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends. The assumptions used to determine the fair value of the stock based awards are management’s best estimates and involve inherent uncertainties and the application of judgment.
Recently issued accounting pronouncements	N. Recently issued accounting pronouncements As an emerging growth company, the Jumpstart Our Business Startup Act of 2012 (the “JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The Company adopted the following accounting standards during the year: On January 1, 2023, the Company adopted ASU No. 2016-13, “ Financial Instruments – Credit Losses The following are accounting pronouncements that are not yet effective for the Company: In August 2020, FASB issued ASU 2020-06, “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging- Contracts in Entity’s Own Equity (Subtopic 815-40).” The amendments in this update affect entities that issue convertible instruments and/or contracts in an entity’s own equity. For convertible instruments, the instruments primarily affected are those issued with beneficial conversion features or cash conversion features because the accounting models for those specific features are removed. This ASU is effective for the Company starting on January 1, 2024. The Company does not believe that the adoption of this standard will have a material impact on the Company’s financial statements. In November 2023, the FASB issued ASU 2023-07, “ Segment Reporting (Topic 280) In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) – “ Improvements to Income Tax Disclosures
Revenue recognition	O. Revenue recognition Revenue is recognized when (or as) control of the promised goods or services is transferred to the customer, and in an amount that reflects the consideration the Company is contractually due in exchange for those services or goods. The Company follows five steps to record revenue: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the Company satisfies its performance obligations. The Company’s revenues consist of sales of drone safety systems (“products”) with a one-year warranty, directly to system manufactures, resellers and an online store. The payments terms are usually an advance payment through a credit card, bank wire or 30 days credit upon delivery of the product for certain existing clients. The Company recognizes revenue from the sale of products at the point of time when control is transferred to its customers. Once the products have been physically delivered to the agreed location, the Company no longer has physical pos but has a present right to receive payment without retaining any significant risks or benefits. The products include warranties that require the Company to either replace or repair defective products during the warranty period if the products fail to comply with their described specifications. Such warranties are not accounted for as separate performance obligations and hence no revenue is allocated to them. Instead, a provision is made for the costs of satisfying the warranties.
Cost of sales	Q. Cost of sales Cost of sales consists primarily of expenses related to the purchase of materials of products sold, royalties, warranty costs, salary and related expenses.
Research and development cost	R. Research and development cost Research and development expenses consist primarily of payroll, payroll related expenses, subcontractors, and materials. Costs are expensed as incurred.
Leases	S. Leases The Company accounts for leases in accordance with ASC 842 “ Leases . The Company has elected the practical expedient to include lease and non-lease components as a single lease component. Additionally, the Company has made a policy election not to recognize operating lease right-of- use assets and lease liabilities on leases with original terms of 12 months or less. Payments for variable lease costs are expensed as incurred and are not included in the operating lease ROU assets and lease liabilities. In accordance with ASC 360-10, management reviews operating lease assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable based on estimated future undiscounted cash flows. If so indicated, an impairment loss would be recognized for the difference between the carrying amount of the asset and its fair value.
Income taxes	U. Income taxes The Company accounts for income taxes in accordance with ASC 740 (Income Taxes) (“ASC 740”). Deferred taxes are determined utilizing the assets and liabilities method, which is based on the estimated future tax effects of the differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all the deferred tax assets will not be realized. The measurement of deferred tax assets is reduced, if necessary, by the amount of any tax benefits that, based on available evidence, are not expected to be realized. As of December 31, 2023 and 2022, the Company recorded a full valuation allowance against its deferred tax assets. The Company applies ASC 740, which clarifies the accounting and reporting for uncertainties with respect to income taxes. ASC 740 prescribes a comprehensive model for the financial statement recognition, measurement, presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. As of December 31, 2023 and 2022, no liability for uncertain tax positions were recorded.
Severance pay	V. Severance payIsraeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. All of the Company’s employees are covered under Section 14 of the Severance Pay Law, 1963 (“Section 14”). Pursuant to Section 14, the Company’s employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with Section 14 relieve the Company from any future severance payments in respect of those employees.
Commitments and contingencies	W. Commitments and contingencies Liabilities for loss contingencies arising from claims, assessments, litigations, fines and penalties and other sources are recognized in accordance with ASC No. 450, “ Contingencies
Basic and diluted loss per share	X. Basic and diluted loss per share Loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares outstanding during
Concentration of Credit Risk	Y. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents.

Significant Accounting Polici_2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Significant Accounting Policies [Abstract]
Schedule of Property and Equipment, Net	Depreciation is calculated on a straight-line basis, over the useful lives of the assets at annual rates as follows: Years Computers 3-7 Research and Development equipment 6-7 Furniture and office equipment 17 Leasehold improvements Shorter of economic life or remaining lease term

Other Current Assets (Tables)

Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Other Current Assets [Abstract]
Schedule of Other Current Assets	December 31 2023 2022 Governmental institutions 233,501 120,126 Prepaid expenses 349,632 59,415 Other current assets 68,427 - Total 651,560 179,541

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2023
Inventories [Abstract]
Schedule of Inventories	December 31 2023 2022 Raw materials 261,192 284,028 Finished goods 3,276 20,791 Total 264,468 304,823

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Leases [Abstract]
Schedule of Lease Expenses	The Company’s lease expenses were as follows: Year ended 2023 2022 2021 Lease expense $ 45,891 $ 47,425 $ 50,103
Schedule of Other Information Related to Operating Leases	Other information related to operating leases as follows: December 31, 2023 2022 2021 Weighted-average remaining lease term — operating leases (years) 0.166 1.166 1.166 Weighted-average discount rate — operating leases (%) 6.00 6.00 6.00
Schedule of Undiscounted Maturities of Operating Lease Payments	Undiscounted maturities of operating lease payments are summarized as follows: December 31, 2024 $ 8,126 Total undiscounted cash flows $ 8,126 Less: imputed interest $ 583 Operating lease liabilities $ 7,543

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2023
Property and Equipment, Net [Abstract]
Schedule of Property and Equipment, Net	Leasehold improvements Computers Furniture and office equipment R&D equipment Total Cost: Balance as of January 1, 2022 94,805 5,572 30,596 — 130,973 Additions during the year — 9,725 — — 9,725 Balance as of December 31, 2022 94,805 15,297 30,596 — 140,698 Additions during the year — 9,037 677 16,043 25,757 Balance as of December 31, 2023 94,805 24,334 31,273 16,043 166,455 Accumulated depreciation: Balance as of January 1, 2022 69,213 3,586 8,093 — 80,892 Additions during the year 14,216 1,774 2,505 — 18,495 Balance as of December 31, 2022 83,429 5,360 10,598 — 99,387 Additions during the year 9,490 4,026 2,548 1,023 17,087 Balance as of December 31, 2023 92,919 9,386 13,146 1,023 116,474 Net book value: As of December 31, 2023 1,886 14,948 18,127 15,020 49,981 As of December 31, 2022 11,376 9,937 19,998 — 41,311

Other Accounts Payable (Tables)

Other Accounts Payable (Tables)	12 Months Ended
	Dec. 31, 2023
Other Accounts Payable [Abstract]
Schedule of Other Accounts Payable	December 31 2023 2022 Employees, salaries and related liabilities 195,509 137,597 Advances from customers 201,762 185,002 Warranty provision 5,793 9,136 Accrued expenses 287,797 442,912 690,861 774,647

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Compensation [Abstract]
Schedule of Stock Option Activity	A summary of the stock option activity for the year ended December 31, 2023 is as follows: Number of Weighted Options outstanding as of December 31, 2022 - Granted 366,172 $ 1.275 Options outstanding as of December 31, 2023 366,172 $ 1.275 Options exercisable as of December 31, 2023 - $ -
Schedule of Grand Date Fair Value of Options Granted	The Company used the Black-Scholes option-pricing model to determine the fair value of options granted during 2023. The following assumptions were applied in determining the options’ fair value on their grant date: 2023 Risk-free interest rate 4.51%-4.67% Expected option term (years) 3.8-5 Expected share price volatility 61.1%-66.3 % Dividend yield -

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2023
Warrants [Abstract]
Schedule of Fair Value of Series A Warrants Issued Performing Numerous Iterations Using Black–Scholes Option Price Model	The fair value of the series A warrants issued in the PIPE at the time of the initial closing, which took place on October 30, 2023, and on December 31, 2023, was calculated by an independent valuation expert, performing numerous iterations using the Black–Scholes option price model, based on a probability of a down round protection adjustment event and using the following assumptions: October 30, December 31, Expected volatility (%) 55.95%-59.37% 55.08%-60.24 Risk-free interest rate (%) 4.78%-4.99% 3.85%-4.05% Expected Life (years) 2-5 2-5 Value per share $0.59 $0.71 Exercise price (U.S. dollars per share) $1.1 $1.1
Schedule of Fair Value Changes of the Series A Warrants	The following table sets forth the fair value changes of the series A warrants during the year ended December 31, 2023: Balance as of December 31, 2022 - Initial measurement 1,287,173 Change in fair value 277,600 Balance as of December 31, 2023 1,564,773
Schedule of Warrants Issued	Warrants issued as part of the Delta Drone transaction with the Former Parent Company and upon the IPO completion: Issuance date In connection with No. of Exercise No. of 2022* Delta Drone Warrants 111,261 $ 4.00 111,261 2023** IPO Underwriter Warrants 97,500 $ 5.00 97,500 2023*** IPO Consultants Warrants 359,020 $ 0.00555 359,020 2023**** IPO Consultants Warrants 144,606 $ 1.275 144,606 * see Note 12B ** see Note 9C2) *** see Note 9C4) **** see Note 9C5)

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Taxes [Abstract]
Schedule of Company’s Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2023 2022 Net operating loss carry forward $ 3,612,947 $ 2,693,459 Research and development expenses 145,249 135,367 Provision for warranty 1,332 2,101 Provision for vacation and convalescence 17,459 15,799 Issuance cost 81,010 86,464 Total deferred tax assets 3,857,998 2,933,190 Less - valuation allowance (3,857,998 ) (2,933,190 ) Net deferred tax assets $ - $ -

General (Details)

General (Details) - USD ($)			1 Months Ended	12 Months Ended
	Oct. 30, 2023	Jul. 31, 2023	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
General [Line Items]
Accumulated losses (in Dollars)				$ (18,423,057)	$ (14,651,678)
Shareholders’ equity (in Dollars)				$ 6,105,058	(1,641,930)	$ (6,616,292)	$ (6,000,911)
Accumulated deficit (in Dollars)					(1,600,000)
Simple agreements for future equity (in Dollars)					$ 1,515,000
Gross proceeds (in Dollars)	$ 5,100,000	$ 7,800,000
Number of warrants issued	3,500,000
Purchase of ordinary shares	1
Cashless exercise				8,257
Investors received				2,876,957
IPO [Member]
General [Line Items]
Gross proceeds (in Dollars)	$ 5,100,000	$ 7,800,000
Shares issue and sold		1,950,000
Ordinary shares issued					179,510
Pre-funded warrants				111,261
Pre-Funded Warrants [Member]
General [Line Items]
Pre-funded warrants				605,452
Ordinary Shares [Member]
General [Line Items]
Shares issue and sold	1,136,364
Series A warrants [Member]
General [Line Items]
Number of warrants issued	4,636,364
Pre-funded warrants				4,636,364
Series B warrants [Member]
General [Line Items]
Number of warrants issued	140,373
Ordinary shares issued				8,217
Pre-funded warrants				132,116
Warrant [Member]
General [Line Items]
Pre-funded warrants exercised shares				2,894,548
Credit Facility Agreement [Member]
General [Line Items]
Aggregate initial amount (in Dollars)			$ 745,000

Significant Accounting Polici_3

Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Significant Accounting Policies [Line Items]
Depreciation expense	$ 17,087	$ 18,495	$ 17,627
Prospective initial public offering expenses	345,925	389,396
Other accounts payable warranty provision	$ 5,793	$ 9,136
Employee Severance [Member]
Significant Accounting Policies [Line Items]
Employees monthly deposits rate	8.33%

Significant Accounting Polici_4

Significant Accounting Policies (Details) - Schedule of Property and Equipment, Net	12 Months Ended
	Dec. 31, 2023
Computers [Member] | Minimum [Member]
Schedule of Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	3 years
Computers [Member] | Maximum [Member]
Schedule of Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	7 years
Research and Development Equipment [Member] | Minimum [Member]
Schedule of Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	6 years
Research and Development Equipment [Member] | Maximum [Member]
Schedule of Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	7 years
Furniture and Office Equipment [Member]
Schedule of Property, Plant and Equipment [Line Items]
Property and equipment, useful lives	17 years
Leasehold Improvements [Member]
Schedule of Property, Plant and Equipment [Line Items]
Leasehold improvements	Shorter of economic life or remaining lease term

Other Current Assets (Details)

Other Current Assets (Details) - Schedule of Other Current Assets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Other Accounts Receivable [Abstract]
Governmental institutions	$ 233,501	$ 120,126
Prepaid expenses	349,632	59,415
Other current assets	68,427
Total	$ 651,560	$ 179,541

Inventories (Details)

Inventories (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Inventories [Abstract]
Wrote off inventory	$ 33,360	$ 12,387

Inventories (Details) - Schedul

Inventories (Details) - Schedule of Inventories - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Inventories [Abstract]
Raw materials	$ 261,192	$ 284,028
Finished goods	3,276	20,791
Total	$ 264,468	$ 304,823

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Mar. 31, 2024	Feb. 29, 2024
Lease [Line Items]
Lease payment	$ 50
Forecast [Member]
Lease [Line Items]
Lease agreement		1 month	2 years

Leases (Details) - Schedule of

Leases (Details) - Schedule of Lease Expenses - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Company’s Lease Expenses [Abstract]
Lease expense	$ 45,891	$ 47,425	$ 50,103

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of Other Information Related to Operating Leases	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Schedule of Other Information Related to Operating Leases [Abstract]
Weighted-average remaining lease term — operating leases	1 month 30 days	1 year 1 month 30 days	1 year 1 month 30 days
Weighted-average discount rate — operating leases	6%	6%	6%

Leases (Details) - Schedule o_3

Leases (Details) - Schedule of Undiscounted Maturities of Operating Lease Payments - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Undiscounted Maturities of Operating Lease Payments [Abstract]
2024	$ 8,126
Total undiscounted cash flows	8,126
Less: imputed interest	583
Operating lease liabilities	$ 7,543	$ 45,097

Property and Equipment, Net (De

Property and Equipment, Net (Details) - Schedule of Property and Equipment, Net - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cost [Member]
Cost:
Cost, Begining Balance	$ 140,698	$ 130,973
Cost, Additions during the year	25,757	9,725
Cost, Ending Balance	166,455	140,698
Accumulated depreciation [Member]
Accumulated depreciation:
Accumulated depreciation, Begining Balance	99,387	80,892
Accumulated depreciation, Addition	17,087	18,495
Accumulated depreciation, Ending Balance	116,474	99,387
Net Book Value [Member]
Accumulated depreciation:
Net book value	49,981	41,311
Leasehold improvements [Member] | Cost [Member]
Cost:
Cost, Begining Balance	94,805	94,805
Cost, Additions during the year
Cost, Ending Balance	94,805	94,805
Leasehold improvements [Member] | Accumulated depreciation [Member]
Accumulated depreciation:
Accumulated depreciation, Begining Balance	83,429	69,213
Accumulated depreciation, Addition	9,490	14,216
Accumulated depreciation, Ending Balance	92,919	83,429
Leasehold improvements [Member] | Net Book Value [Member]
Accumulated depreciation:
Net book value	1,886	11,376
Computers [Member] | Cost [Member]
Cost:
Cost, Begining Balance	15,297	5,572
Cost, Additions during the year	9,037	9,725
Cost, Ending Balance	24,334	15,297
Computers [Member] | Accumulated depreciation [Member]
Accumulated depreciation:
Accumulated depreciation, Begining Balance	5,360	3,586
Accumulated depreciation, Addition	4,026	1,774
Accumulated depreciation, Ending Balance	9,386	5,360
Computers [Member] | Net Book Value [Member]
Accumulated depreciation:
Net book value	14,948	9,937
Furniture and office equipment [Member] | Cost [Member]
Cost:
Cost, Begining Balance	30,596	30,596
Cost, Additions during the year	677
Cost, Ending Balance	31,273	30,596
Furniture and office equipment [Member] | Accumulated depreciation [Member]
Accumulated depreciation:
Accumulated depreciation, Begining Balance	10,598	8,093
Accumulated depreciation, Addition	2,548	2,505
Accumulated depreciation, Ending Balance	13,146	10,598
Furniture and office equipment [Member] | Net Book Value [Member]
Accumulated depreciation:
Net book value	18,127	19,998
R&D equipment [Member] | Cost [Member]
Cost:
Cost, Begining Balance
Cost, Additions during the year	16,043
Cost, Ending Balance	16,043
R&D equipment [Member] | Accumulated depreciation [Member]
Accumulated depreciation:
Accumulated depreciation, Begining Balance
Accumulated depreciation, Addition	1,023
Accumulated depreciation, Ending Balance	1,023
R&D equipment [Member] | Net Book Value [Member]
Accumulated depreciation:
Net book value	$ 15,020

Convertible Notes (Details)

Convertible Notes (Details)			12 Months Ended
	Jul. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2023 AUD ($)
Convertible Notes [Line Items]
Stock Issued During Period, Value, Conversion of Units		$ 1,514,928		$ 6,423,308
Initial Public Offering Price Discounted Percentage			25%
Percentage Of Discount On Purchase Amount			20%
Percentage Of Discount On Investment Percentage			20%
Divided amount			$ 2.3			$ 3.313
Aggregate amount	$ 1,514,928	$ 1,514,928		1,514,928
Percentage of converted price	25%
Converted into ordinary shares | shares	504,976
Change in the fair value of conversion			504,976
Convertible Debt [Member]
Convertible Notes [Line Items]
Change in the fair value of conversion			$ 504,976

Other Accounts Payable (Details

Other Accounts Payable (Details) - Schedule of Other Accounts Payable - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Other Accounts Payable [Abstract]
Employees, salaries and related liabilities	$ 195,509	$ 137,597
Advances from customers	201,762	185,002
Warranty provision	5,793	9,136
Accrued expenses	287,797	442,912
Total	$ 690,861	$ 774,647

Shareholders' Equity (Deficit)

Shareholders' Equity (Deficit) (Details)

1 Months Ended

12 Months Ended

Dec. 14, 2023 shares

Oct. 26, 2023 USD ($)

Jul. 31, 2023 $ / shares shares

Oct. 02, 2022 shares

May 23, 2022 shares

Feb. 02, 2022 USD ($) $ / shares

Jan. 28, 2022 shares

Dec. 31, 2023 USD ($) $ / shares shares

Dec. 31, 2023 USD ($) $ / shares shares

Dec. 31, 2022 USD ($) $ / shares shares

Dec. 31, 2021 USD ($)

Dec. 31, 2023 ₪ / shares

Dec. 31, 2022 ₪ / shares

Sep. 25, 2022 ILS (₪) shares

Shareholders' Equity (Deficit) [Line Items]

Equity instruments amount (in Dollars) | $

$ 975,811

$ 3,795,338

Fair value amount (in Dollars) | $

$ 1,287,173

1,287,173

Net issuance expenses (in Dollars) | $

3,066,656

Fair value warrants (in Dollars) | $

277,600

Ordinary shares, par value (in New Shekels per share) | ₪ / shares

₪ 0.02

₪ 0.02

Ordinary per share (in Dollars per share) | $ / shares

$ 0.00555

Share-based compensation expenses (in Dollars) | $

$ 14,815

$ 52,286

Stockholders equity reverse stock split

On June 26, 2022, the shareholders of the Company approved a 1-for-2 reverse stock split of the Company’s Ordinary Shares, pursuant to which holders of Ordinary Shares received one Ordinary Share, par value NIS 0.02, for every two ordinary shares, par value NIS 0.01, held before the reverse stock split.

Private Placement [Member]

Shareholders' Equity (Deficit) [Line Items]

Gross proceeds (in Dollars) | $

$ 5,100,000

Warrant ordinary shares

1,136,364

Pre-funded warrants purchase shares

3,500,000

Purchase ordinary share

1

1

Warrant, description

each to purchase one Ordinary Share at an exercise price of $1.10 per Ordinary Share (subject to customary adjustments and certain anti-dilution adjustments), and were immediately exercisable for a period of 5.5 years from the date of issuance.

Purchasers subject to a pricing floor price (in Dollars per share) | $ / shares

$ 0.5

Comprehensive loss (in Dollars) | $

$ 247,129

Private Placement [Member] | Warrant [Member]

Shareholders' Equity (Deficit) [Line Items]

Pre-funded warrants purchase shares

2,894,548

Private Placement [Member] | Pre-Funded Warrants [Member]

Shareholders' Equity (Deficit) [Line Items]

Remaining outstanding shares

605,452

IPO [Member]

Shareholders' Equity (Deficit) [Line Items]

Gross proceeds (in Dollars) | $

$ 7,800,000

Warrant exercise price (in Dollars per share) | $ / shares

$ 4

$ 4

Warrant shares

111,261

111,261

Sale closing shares issued

1,950,000

Sale of stock price per share (in Dollars per share) | $ / shares

$ 4

Aggregate purchase shares

292,500

Offering expenses net proceeds (in Dollars) | $

$ 5,800,000

Deferred underwriting commissions (in Dollars) | $

800,000

Offering costs (in Dollars) | $

$ 1,200,000

1,200,000

$ 39,091

Aggregate amount (in Dollars) | $

$ 1,514,928

Converted shares

504,976

Converted value (in Dollars) | $

$ 2,019,904

Fair value warrants (in Dollars) | $

387,660

Repaid credit facility (in Dollars) | $

745,000

Bonus shares issued

179,510

Share-based compensation expenses (in Dollars) | $

$ 296,283

$ 91,377

Warrants shares issued

144,606

144,606

Warrant exercisable shares

1

Fair value of the warrants (in Dollars) | $

$ 85,318

IPO [Member] | Maximum [Member]

Shareholders' Equity (Deficit) [Line Items]

Share capital (in New Shekels) | ₪

₪ 500,000

Capital units authorized

25,000,000

IPO [Member] | Minimum [Member]

Shareholders' Equity (Deficit) [Line Items]

Share capital (in New Shekels) | ₪

₪ 400,000

Capital units authorized

20,000,000

IPO [Member] | Warrant [Member]

Shareholders' Equity (Deficit) [Line Items]

Warrant exercise price (in Dollars per share) | $ / shares

$ 5

$ 1.275

$ 1.275

Aggregate purchase shares

97,500

Fair value warrants (in Dollars) | $

$ 93,600

Warrant exercisable shares

1

Parent Company [Member]

Shareholders' Equity (Deficit) [Line Items]

Converted value (in Dollars) | $

$ 10,000,000

Ordinary shares, par value (in New Shekels per share) | $ / shares

$ 2.7797

Ordinary shares issued

3,237,700

Series A warrants [Member] | Private Placement [Member]

Shareholders' Equity (Deficit) [Line Items]

Warrant ordinary shares

0.005

Remaining outstanding shares

4,636,364

Series B warrants [Member]

Shareholders' Equity (Deficit) [Line Items]

Warrant exercise price (in Dollars per share) | $ / shares

$ 0.005

$ 0.005

Series B warrants [Member] | Private Placement [Member]

Shareholders' Equity (Deficit) [Line Items]

Warrant ordinary shares

140,373

Warrant aggregate shares

5,563,638

Remaining outstanding shares

132,116

Series B warrants [Member] | Private Placement [Member] | Warrant [Member]

Shareholders' Equity (Deficit) [Line Items]

Warrant aggregate shares

140,373

Warrant shares

8,257

8,257

Series B warrants [Member] | Private Placement [Member] | Warrant [Member] | Maximum [Member]

Shareholders' Equity (Deficit) [Line Items]

Warrants cashless exercise shares

2,876,957

Series B warrants [Member] | Private Placement [Member] | Warrant [Member] | Minimum [Member]

Shareholders' Equity (Deficit) [Line Items]

Warrants cashless exercise shares

8,217

Board of Directors [Member]

Shareholders' Equity (Deficit) [Line Items]

Bonus shares issued

672,691

4,178,206

Stock split conversion ratio

0.23

2.5

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($)		12 Months Ended
	Sep. 20, 2023	Dec. 31, 2023
Share-Based Compensation [Line Items]
Ordinary shares reserved		610,156
Ordinary shares available for future awards		243,984
Aggregate options	366,172	366,172
Options exercise price	$ 1.275
Exercisable grant date	5 years
Share based options vested	4 years
Fair value of granted value		$ 212,199
Weighted-average remaining contractual life of outstanding options		4 years 8 months 12 days
Unrecognized compensation cost related to unvested options		$ 197,384
Share based expected to be recognized weighted-average period		3 years 9 months 18 days
Share based intrinsic value of options expected to vest		$ 0
Second Anniversary Vesting [Member]
Share-Based Compensation [Line Items]
Share based granted vesting options, percentage	50%
Share-Based Payment Arrangement [Member]
Share-Based Compensation [Line Items]
Share based unvested options		366,172
Share-Based Payment Arrangement [Member] | Second Anniversary Vesting [Member]
Share-Based Compensation [Line Items]
Share based granted vesting options, percentage	6.25%

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of Stock Option Activity - $ / shares		12 Months Ended
	Sep. 20, 2023	Dec. 31, 2023
Schedule of Stock Option Activity [Abstract]
Options outstanding as of ending
Options outstanding as of ending
Granted	366,172	366,172
Granted		$ 1.275
Options outstanding as of ending		366,172
Options outstanding as of ending		$ 1.275
Options exercisable
Options exercisable

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of Grand Date Fair Value of Options Granted	12 Months Ended
	Dec. 31, 2023
Stock-Based Compensation (Details) - Schedule of Grand Date Fair Value of Options Granted [Line Items]
Dividend yield
Minimum [Member]
Stock-Based Compensation (Details) - Schedule of Grand Date Fair Value of Options Granted [Line Items]
Risk-free interest rate	4.51%
Expected option term (years)	3 years 9 months 18 days
Expected share price volatility	61.10%
Maximum [Member]
Stock-Based Compensation (Details) - Schedule of Grand Date Fair Value of Options Granted [Line Items]
Risk-free interest rate	4.67%
Expected option term (years)	5 years
Expected share price volatility	66.30%

Warrants (Details) - Schedule o

Warrants (Details) - Schedule of Fair Value of Series A Warrants Issued Performing Numerous Iterations Using Black–Scholes Option Price Model - Warrants [Member] - $ / shares		12 Months Ended
	Oct. 30, 2023	Dec. 31, 2023
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Value per share (in Dollars per share)	$ 0.59	$ 0.71
Exercise price (in Dollars per share)	$ 1.1	$ 1.1
Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected volatility	55.95%	55.08%
Risk-free interest rate	4.78%	3.85%
Expected Life	2 years	2 years
Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected volatility	59.37%	60.24%
Risk-free interest rate	4.99%	4.05%
Expected Life	5 years	5 years

Warrants (Details) - Schedule_2

Warrants (Details) - Schedule of Fair Value Changes of the Series A Warrants	12 Months Ended
	Dec. 31, 2023 USD ($)
Schedule of Fair Value Changes of the Series A Warrants [Abstract]
Balance as of December 31, 2022
Initial measurement	1,287,173
Change in fair value	277,600
Balance as of December 31, 2023	$ 1,564,773

Warrants (Details) - Schedule_3

Warrants (Details) - Schedule of Warrants Issued	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Delta Drone Warrants [Member]
Schedule of Warrants Issued [Line Items]
Issuance date	2022*	[1]
In connection with	Delta Drone Warrants	[1]
No. of warrants issued	111,261	[1]
Exercise price per share | $ / shares	$ 4	[1]
No. of Ordinary shares underlying warrants	111,261	[1]
IPO Underwriter Warrants [Member]
Schedule of Warrants Issued [Line Items]
Issuance date	2023**	[2]
In connection with	IPO Underwriter Warrants	[2]
No. of warrants issued	97,500	[2]
Exercise price per share | $ / shares	$ 5	[2]
No. of Ordinary shares underlying warrants	97,500	[2]
IPO Consultants Warrants [Member]
Schedule of Warrants Issued [Line Items]
Issuance date	2023***	[3]
In connection with	IPO Consultants Warrants	[3]
No. of warrants issued	359,020	[3]
Exercise price per share | $ / shares	$ 0.00555	[3]
No. of Ordinary shares underlying warrants	359,020	[3]
IPO Consultants Warrants 1 [Member]
Schedule of Warrants Issued [Line Items]
Issuance date	2023****	[4]
In connection with	IPO Consultants Warrants	[4]
No. of warrants issued	144,606	[4]
Exercise price per share | $ / shares	$ 1.275	[4]
No. of Ordinary shares underlying warrants	144,606	[4]
[1]see Note 12B[2]see Note 9C2)[3]see Note 9C4)[4]see Note 9C5)

Commitments and Contingencies (

Commitments and Contingencies (Details) $ / shares in Units, $ in Millions				12 Months Ended
	Feb. 02, 2022 USD ($) $ / shares shares	Jan. 28, 2022 USD ($)	Jan. 28, 2022 AUD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2023 ₪ / shares shares	Dec. 31, 2023 $ / shares shares	Dec. 31, 2022 ₪ / shares shares
Commitments and Contingencies [Abstract]
Total consideration		$ 4,200,000
Ordinary shares (in Shares) | shares						10,073,956	10,073,956	3,597,442
Ordinary per shares (in Dollars per share) | ₪ / shares						₪ 0.02		₪ 0.02
IPO [Member]
Commitments and Contingencies [Abstract]
Converted value (in Dollars)				$ 2,019,904
Warrant outstanding (in Shares) | shares						111,261	111,261
Warrant exercise price (in Dollars per share) | $ / shares							$ 4
Israel Innovation Authority [Member]
Commitments and Contingencies [Abstract]
Research and development grant received				300%
Grant received (in Dollars)					$ 748,000
Royalties payment (in Dollars)				$ 121,000
Minimum [Member] | Israel Innovation Authority [Member]
Commitments and Contingencies [Abstract]
Royalties rate				3%
Maximum [Member] | Israel Innovation Authority [Member]
Commitments and Contingencies [Abstract]
Royalties rate				3.50%
Grant received (in Dollars)				$ 613,000
Former Parent Company [Member]
Commitments and Contingencies [Abstract]
Sale percentage		100%	100%
Total consideration			$ 6
Ordinary shares (in Shares) | shares	111,261
Ordinary per shares (in Dollars per share) | $ / shares	$ 2.7797
Converted value (in Dollars)	$ 10,000,000
Former Parent Company [Member] | IPO [Member]
Commitments and Contingencies [Abstract]
Ordinary shares percentage	50%
Bank of Israel [Member]
Commitments and Contingencies [Abstract]
Bear interest rate						0.72%	0.72%

Loan from Related Party (Detail

Loan from Related Party (Details) - USD ($)				1 Months Ended	6 Months Ended	12 Months Ended
	Jun. 26, 2023	Oct. 30, 2022	Aug. 31, 2022	Aug. 31, 2023	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Loan from Related Party [Line Items]
Loan payment received					$ 745,000
Aggregate initial amount				$ 745,000
Credit facility	$ 745,000
Accumulated interest expenses						$ 7,073	$ 10,396
Medigus [Member]
Loan from Related Party [Line Items]
Loan payment received			$ 250,000				$ 500,000
Interest rate			8%
Loan repaid		$ 250,000
Aggregate initial amount		625,000
Additional payment						$ 40,000
Medigus Loan [Member]
Loan from Related Party [Line Items]
Accrued interest		$ 4,876

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Taxes [Line Items]
Tax year	2017
Standard tax rates	23%
Operating loss carry-forwards (in Dollars)	$ 15.7	$ 12.7
Israel [Member]
Income Taxes [Line Items]
Tax rate	23%	23%	23%

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of Company’s Deferred Tax Assets and Liabilities - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Schedule of Company’s Deferred Tax Assets and Liabilities [Abstract]
Net operating loss carry forward	$ 3,612,947	$ 2,693,459
Research and development expenses	145,249	135,367
Provision for warranty	1,332	2,101
Provision for vacation and convalescence	17,459	15,799
Issuance cost	81,010	86,464
Total deferred tax assets	3,857,998	2,933,190
Less - valuation allowance	(3,857,998)	(2,933,190)
Net deferred tax assets

Transactions with Related Par_2

Transactions with Related Parties (Details) - USD ($)	1 Months Ended		12 Months Ended
	Jul. 31, 2023	Oct. 31, 2022	Dec. 31, 2021	Dec. 31, 2023
Related Party Transaction [Line Items]
Total amount payable				$ 0
Related Party [Member]
Related Party Transaction [Line Items]
Monthly fees	$ 10,000	$ 10,000
Purchased total amount			$ 11,140
Maris-Tech [Member]
Related Party Transaction [Line Items]
Total amount payable				$ 0

Subsequent Events (Details)

Subsequent Events (Details)	1 Months Ended	12 Months Ended
	Jan. 31, 2024 shares	Dec. 31, 2023 ILS (₪)	Feb. 01, 2024 ft²	Jan. 23, 2024 ILS (₪) shares
Subsequent Events [Line Items]
Aggregate rental payment (in New Shekels) | ₪		₪ 71,000
Lessee, Operating Lease, Remaining Lease Term		3 years
Bank guarantee amount (in New Shekels) | ₪		₪ 248,000
Subsequent Event [Member]
Subsequent Events [Line Items]
Registered share capital (in New Shekels) | ₪				₪ 3,500,000
Ordinary shares issued				200,000,000
Pre-funded warrants	605,452
Series B warrants	132,116
Cashless received	601,367
Ordinary shares issued	131,249
Square feet (in Square Feet) | ft²			260
Lease Agreements [Member] | Subsequent Event [Member]
Subsequent Events [Line Items]
Square feet (in Square Feet) | ft²			6,340
Capital Addition Purchase Commitments [Member] | Subsequent Event [Member]
Subsequent Events [Line Items]
Registered share capital (in New Shekels) | ₪				₪ 4,000,000